SCHEMBL1333882

SCHEMBL1333882

CN1Cc2c(Br)cccc2C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.46
CSNK1A1 P48729 1/20 0.46
CDK5 Q00535 1/20 0.46
ROCK1 Q13464 1/20 0.46
DYRK1A Q13627 1/20 0.46
LRRK2 Q5S007 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
PARP10 Q53GL7 1/20 0.43
PARP11 Q9NR21 1/20 0.43
CBLB Q13191 1/20 0.42
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
POLB P06746 2/20 0.38
RECQL P46063 1/20 0.38
GRM1 Q13255 1/20 0.37
BRD4 O60885 1/20 0.37
ROCK2 O75116 1/20 0.36
RAB9A P51151 1/20 0.36
CYP1B1 Q16678 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isobutane SCHEMBL2035704 0.87 CBLB (0.41) PIM1CSNK1A1CDK5ROCK1DYRK1A
SCHEMBL5839859 0.84 POLB (0.50) PIM1CSNK1A1CDK5ROCK1DYRK1A
SCHEMBL29777577 0.84 POLB (0.50) PIM1CSNK1A1CDK5ROCK1DYRK1A
SCHEMBL17520009 0.81 ALDH1A1 (0.46) PARP10PARP11KMT2AMEN1POLB
SCHEMBL21211920 0.79 PIM1 (0.44) PIM1CSNK1A1CDK5ROCK1DYRK1A
SCHEMBL17519985 0.79 MAPK1 (0.51) KMT2AMEN1POLBRECQLGRM1
SCHEMBL19370098 0.79 CRBN (0.48) KMT2AMEN1POLBRECQLROCK2
SCHEMBL25767285 0.79 POLB (0.37) KMT2AMEN1POLBRECQLROCK2
SCHEMBL5906568 0.79 BRD4 (0.47) KMT2AMEN1POLBRECQLBRD4
SCHEMBL25772610 0.79 POLB (0.37) KMT2AMEN1POLBRECQLGRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346609-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES INC (US) 2025-11-13 US disclosed
EP-4613332-A2 COT MODULATORS AND METHODS OF USE THEREOF Gilead Sciences, Inc. (US) 2025-09-10 EP disclosed
WO-2025132946-A1 PHENYLPYRROLIDINE DERIVATIVES AND THEIR USE AS POI-THETA DERIVATIVES BREAKPOINT THERAPEUTICS GMBH (DE) 2025-06-26 WO disclosed
EP-3896064-B1 4,6-DIAMINO-QUINOLINE-3-CARBONITRILE DERIVATIVES AS CANCER OSAKA THYROID (COT) MODULATORS FOR TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS GILEAD SCIENCES INC (US) 2025-05-21 EP disclosed
CN-119143730-A COT modulators and methods of use thereof 吉利德科学公司 2024-12-17 CN disclosed
CN-114380799-B COT modulators and methods of use thereof 吉利德科学公司 2024-10-01 CN disclosed
US-20240254137-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2024-08-01 US disclosed
US-11905299-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2024-02-20 US disclosed
US-20230348456-A1 QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2023-11-02 US disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 US disclosed
EP-1348706-B1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2009-08-19 EP disclosed
WO-2009051417-A2 PHENANTHRENE LACTAM DERIVATIVES HAVING ANTICANCER ACTIVITY AND METHOD FOR THE PREPARATION THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2009-04-23 WO disclosed
US-20060287370-A1 Isoindolinone kinase inhibitors CURTIN MICHAEL L 2006-12-21 US disclosed
US-7129260-B2 Isoindolinone kinase inhibitors ABBOTT LABORATORIES (US) 2006-10-31 US disclosed
US-7067537-B2 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-27 US disclosed
EP-1633710-A1 ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS Abbott Laboratories (US) 2006-03-15 EP disclosed
US-20050026976-A1 Isoindolinone kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed
WO-2004108672-A1 ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-12-16 WO disclosed
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-15 US disclosed
EP-1348706-A1 SUBSTITUTED THIAZOLE DERIVATIVES BEARING 3-PYRIDYL GROUPS, PROCESS FOR PREPARING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-10-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072876-A1 Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof CYP17A1, CYP21A2, HSD17B1 PIM1 932/4885CSNK1A1 394/4885CDK5 1452/4885
US-20060287370-A1 Isoindolinone kinase inhibitors ABL1, LCK, MAP3K7 PIM1 286/4885CSNK1A1 13/4885CDK5 55/4885
US-11731953-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS PIM1 2977/4885CSNK1A1 1612/4885CDK5 209/4885
US-11905299-B2 Cot modulators and methods of use thereof BRDT, THRB, HCCS PIM1 3061/4885CSNK1A1 1606/4885CDK5 88/4885
US-20240254137-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS PIM1 3061/4885CSNK1A1 1606/4885CDK5 88/4885
US-20250346609-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS PIM1 3061/4885CSNK1A1 1606/4885CDK5 88/4885
US-20230348456-A1 QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME CSNK1A1, CSNK1G1, CSNK1G3 PIM1 1086/4885CSNK1A1 1/4885CDK5 11/4885
US-20050026976-A1 Isoindolinone kinase inhibitors ABL1, LCK, MAP3K7 PIM1 286/4885CSNK1A1 13/4885CDK5 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.